Annals of surgical oncology · 2025
Neoadjuvant Endocrine Therapy Use in Estrogen Receptor Positive Breast Cancer: Insights from Practice Shifts During the COVID-19 Pandemic.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Douglas Sasha R, Thomas Samantha M, van den Bruele Astrid Botty, Wang Ton, Parrish Kendra M, Rosenberger Laura H, Plichta Jennifer K, DiNome Maggie L, Chiba Akiko
Аннотация
BACKGROUND: The COVID-19 pandemic restricted operating room availability, prompting the Pandemic Breast Cancer Consortium to issue guidelines on deferring non-urgent surgical procedures. This led to an increased use of neoadjuvant endocrine therapy (NET) for estrogen-receptor positive (ER+) breast cancers. Irrespective of the pandemic, the ACOSOG Z1031 trial demonstrated that NET was effective at downstaging 51% of patients initially ineligible for breast conserving surgery (BCS). Despite this, NET utilization remains low. This study investigates NET use and related outcomes before, during, and after the pandemic.
METHODS: Patients aged ≥ 18 with clinical T1-T4c, N0-3, ER+/HER2- breast cancers were selected from the National Cancer Database and stratified into two groups: NET versus surgery first. The study analyzed trends from 2019 (pre-pandemic) to 2021 (tail-end-pandemic). Logistic regression identified factors associated with NET utilization.
RESULTS: Results showed that 10,935 (3.9%) patients received NET and 272,546 (96.1%) underwent surgery first. NET use peaked in 2020 at 6.4% (vs. 2019 2.3% and 2021 3.2%, P = 0.001). Median time from diagnosis to treatment was significantly shorter in the NET group (1.02 vs. 1.35 months, P = 0.001). Patients with clinical T3-4 disease who received NET versus surgery first had similar rates of BCS and were less likely to receive chemotherapy.
CONCLUSION: The use of NET nearly tripled during the COVID-19 pandemic and was associated with decreased time to treatment and less use of adjuvant chemotherapy. NET could be considered for patients requiring a delay to surgery or for those with higher T-category who desire BCS or are unable to tolerate chemotherapy.
METHODS: Patients aged ≥ 18 with clinical T1-T4c, N0-3, ER+/HER2- breast cancers were selected from the National Cancer Database and stratified into two groups: NET versus surgery first. The study analyzed trends from 2019 (pre-pandemic) to 2021 (tail-end-pandemic). Logistic regression identified factors associated with NET utilization.
RESULTS: Results showed that 10,935 (3.9%) patients received NET and 272,546 (96.1%) underwent surgery first. NET use peaked in 2020 at 6.4% (vs. 2019 2.3% and 2021 3.2%, P = 0.001). Median time from diagnosis to treatment was significantly shorter in the NET group (1.02 vs. 1.35 months, P = 0.001). Patients with clinical T3-4 disease who received NET versus surgery first had similar rates of BCS and were less likely to receive chemotherapy.
CONCLUSION: The use of NET nearly tripled during the COVID-19 pandemic and was associated with decreased time to treatment and less use of adjuvant chemotherapy. NET could be considered for patients requiring a delay to surgery or for those with higher T-category who desire BCS or are unable to tolerate chemotherapy.